Short Bowel Syndrome Clinical Trials | A Drug Pipeline Analysis Report 2024 | Zealand Pharma, and others expected to boost the market

DelveInsight's 'Short Bowel Syndrome Pipeline Insight 2024' report provides comprehensive global coverage of available, marketed, and pipeline Short Bowel Syndrome therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Short Bowel Syndrome pipeline domain.
Download sample pages: https://www.delveinsight.com/report-store/short-bowel-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key Takeaways from the Short Bowel Syndrome Pipeline Report
Over 20+ Short Bowel Syndrome pipeline therapies are in various stages of development, and their anticipated acceptance in the Short Bowel Syndrome market would significantly increase market revenue.
Leading Short Bowel Syndrome companies developing novel drug candidates to improve the Short Bowel Syndrome treatment landscape include Zealand Pharma, and others.
Promising Short Bowel Syndrome pipeline therapies in various stages of development include Glepaglutide, and others.
Short Bowel Syndrome Overview

Short Bowel Syndrome (SBS) is a complex disorder characterized by malabsorption of nutrients and fluids due to a significant portion of the small intestine being surgically removed or not functioning properly. The small intestine is responsible for absorbing nutrients from food and fluids into the bloodstream. When a large portion of it is absent or non-functional, it can lead to nutritional deficiencies and fluid imbalance.

Short Bowel Syndrome Causes:

The primary cause of Short Bowel Syndrome is surgical removal (resection) of a significant portion of the small intestine due to conditions such as:

1. Intestinal ischemia: Reduced blood flow to the intestine leading to tissue death.

2. Crohn's disease: Severe inflammation of the intestine necessitating surgical removal.

3. Trauma: Injury to the intestine requiring surgical intervention.

4. Congenital defects: Birth defects affecting the development or function of the intestine.

Short Bowel Syndrome Signs and Symptoms:

The signs and symptoms of Short Bowel Syndrome can vary depending on the extent of small intestine removed and the remaining functional capacity. They may include:

1. Diarrhea: Frequent, loose, watery stools due to reduced absorption of fluids and nutrients.

2. Malnutrition: Weight loss, deficiencies in vitamins (especially fat-soluble vitamins A, D, E, and K) and minerals (such as calcium, magnesium, and zinc).

3. Dehydration: Electrolyte imbalances and dehydration due to fluid loss in diarrhea.

4. Abdominal cramping: Pain or discomfort in the abdomen, often associated with diarrhea.

5. Fatigue: Due to malabsorption of nutrients necessary for energy production.

6. Steatorrhea: Foul-smelling, greasy stools due to malabsorption of fats.

Short Bowel Syndrome Diagnosis:

Diagnosing Short Bowel Syndrome involves a combination of clinical evaluation, laboratory tests, imaging studies, and functional tests:

1. Medical History and Physical Examination: Including assessment of symptoms and previous surgical history.

2. Blood Tests: To assess nutritional status, electrolyte levels, and liver function.

3. Stool Studies: To evaluate fat content (fecal fat test) and presence of bacteria that may contribute to diarrhea.

4. Imaging Studies: Such as abdominal ultrasound, CT scan, or MRI to assess the anatomy of the intestine and any residual bowel length.

5. Functional Tests: Including absorption tests (e.g., D-xylose absorption test) to evaluate the intestine's ability to absorb specific nutrients.

Short Bowel Syndrome Treatment Options:

Treatment for Short Bowel Syndrome focuses on managing symptoms, preventing complications, and optimizing nutritional status:

1. Nutritional Support:
- Dietary modifications: High-calorie, low-fat diet with small, frequent meals. Emphasis on easily digestible foods and oral rehydration solutions.
- Enteral nutrition: Tube feeding into the stomach or small intestine to provide nutrients directly.
- Parenteral nutrition: Intravenous (IV) feeding of nutrients and fluids for individuals who cannot tolerate enteral nutrition or have insufficient intestinal function.

2. Medications:
- Antidiarrheal medications: Such as loperamide to reduce diarrhea.
- Vitamin and mineral supplements: To address deficiencies, especially fat-soluble vitamins and electrolytes.

3. Surgical Options:
- Intestinal lengthening procedures: Surgical techniques to maximize the remaining intestine's absorptive capacity.
- Intestinal transplantation: For severe cases of Short Bowel Syndrome where other treatments have not been effective.

4. Management of Complications:
- Close monitoring and management of fluid and electrolyte balance, liver function, and bone health.
- Treatment of complications such as bacterial overgrowth or intestinal motility disorders.

5. Supportive Care:
- Ongoing monitoring by a multidisciplinary team including gastroenterologists, dietitians, pharmacists, and specialized nurses.
- Education and support for patients and caregivers on managing symptoms, nutrition, and medications.

Short Bowel Syndrome Market Outlook:

The prognosis for individuals with Short Bowel Syndrome depends on the extent of intestinal resection, remaining intestinal function, and response to treatment. With appropriate management and support, many people with Short Bowel Syndrome can achieve adequate nutrition and quality of life. However, lifelong monitoring and management are often necessary to prevent complications and optimize overall health.

Short Bowel Syndrome Pipeline Analysis: Drug Profile
Glepaglutide: Zealand Pharma
Glepaglutide is a long-acting GLP-2 analog in development as a potential treatment option for short bowel syndrome (SBS). Glepaglutide is being developed as a liquid product in an autoinjector designed for subcutaneous administration, aimed to reduce, or eliminate, the need for parenteral support in people living with SBS. Currently the product is in Phase III stage of development for the treatment of Short Bowel Syndrome
Discover more about the emerging Short Bowel Syndrome drugs @ https://www.delveinsight.com/sample-request/short-bowel-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Short Bowel Syndrome Key Companies
Zealand Pharma
Short Bowel Syndrome Pipeline Therapies
Glepaglutide
Short Bowel Syndrome Pipeline Therapeutics Assessment
By development stage
By product type
By route of administration
By molecule type
By MOA type
Scope of the Short Bowel Syndrome Pipeline Report
Coverage: Global
Key Short Bowel Syndrome Companies: Zealand Pharma, and others
Key Short Bowel Syndrome Pipeline Therapies: Glepaglutide, and others
Find out more about the Short Bowel Syndrome treatment options in development @ https://www.delveinsight.com/sample-request/short-bowel-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents
1. Introduction
2. Executive Summary
3. Overview
4. Pipeline Therapeutics
5. Late-Stage Products (Phase III)
6. Mid-Stage Products (Phase II)
7. Early Stage Products (Phase I/II)
8. Preclinical Stage Products
9. Discovery Stage Products
10. Therapeutic Assessment
11. Inactive Products
12. Collaborations Assessment- Licensing / Partnering / Funding
13. Unmet Needs
14. Market Drivers and Barriers
15. Appendix
16. About DelveInsight
Trending Reports By DelveInsight:

Functional Constipation Market
https://www.delveinsight.com/report-store/chronic-constipation-market

Lebers Hereditary Optic Neuropathy Lhon Market https://www.delveinsight.com/report-store/lebers-hereditary-optic-neuropathy-lhon-market

Gastric Neuroendocrine Tumors Market
https://www.delveinsight.com/report-store/gastric-neuroendocrine-tumors-market

Immune Thrombocytopenic Purpura Market
https://www.delveinsight.com/report-store/immune-thrombocytopenia-itp-market

Visceral Pain Associated With GI Disorders Market
https://www.delveinsight.com/report-store/visceral-pain-associated-with-gi-disorders-market

Bullous Pemphigoid Market
https://www.delveinsight.com/report-store/bullous-pemphigoid-market

Cyclin-dependent Kinase-like 5 Deficiency Disorder Market https://www.delveinsight.com/infographics/cyclin-dependent-kinase-like-5-cdkl5-deficiency-disorder-market

Myocarditis Market
https://www.delveinsight.com/report-store/myocarditis-market

Recurrent Blood Clots Market
https://www.delveinsight.com/report-store/recurrent-blood-clots-thrombophilia-market

Zollinger-ellison Syndrome Market
https://www.delveinsight.com/report-store/zollinger-ellison-syndrome-market

Age-related Hearing Loss Medical Device Market
https://www.delveinsight.com/blog/age-related-hearing-loss-device-market

Heart Sounds Sensors Market
https://www.delveinsight.com/report-store/heart-sounds-sensors-electronic-stethoscope-market

Hypoplastic Left Heart Syndrome Hlhs Market
https://www.delveinsight.com/report-store/hypoplastic-left-heart-syndrome-market

Infectious Arthritis/Septic Arthritis Market
https://www.delveinsight.com/report-store/infectious-arthritisseptic-arthritis-market

Plasmacytoma Market
https://www.delveinsight.com/report-store/plasmacytoma-market

Agoraphobia Market
https://www.delveinsight.com/report-store/agoraphobia-market

Clinically Isolated Syndrome CIS Market
https://www.delveinsight.com/report-store/clinically-isolated-syndrome-cis-market

Fucosidosis Market
https://www.delveinsight.com/report-store/fucosidosis-market

Major Depressive Disorder Market
https://www.delveinsight.com/report-store/major-depressive-disorder-market

Neuronal Ceroid-lipofuscinoses Market
https://www.delveinsight.com/report-store/neuronal-ceroid-lipofuscinoses-cln1-disease-market

Orthotic Devices Market
https://www.delveinsight.com/report-store/orthotic-devices-market

Contact Us
Kritika Rehani
info@delveinsight.com
+14699457679

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences.

This release was published on openPR.